Kepler Cheuvreux Suisse SA Takes $7.54 Million Position in AbbVie Inc. $ABBV

Kepler Cheuvreux Suisse SA purchased a new position in shares of AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 32,563 shares of the company’s stock, valued at approximately $7,540,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Diversified Trust Co lifted its position in shares of AbbVie by 23.6% in the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after acquiring an additional 10,891 shares in the last quarter. Permanent Capital Management LP acquired a new stake in shares of AbbVie during the third quarter valued at $720,000. Railway Pension Investments Ltd increased its position in AbbVie by 33.0% during the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after purchasing an additional 211,800 shares in the last quarter. World Investment Advisors raised its stake in AbbVie by 9.4% in the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after purchasing an additional 9,811 shares during the last quarter. Finally, Charles Schwab Trust Co raised its stake in AbbVie by 93.4% in the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock valued at $7,434,000 after purchasing an additional 15,502 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ABBV shares. Berenberg Bank set a $275.00 price target on shares of AbbVie in a research note on Tuesday, January 20th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Scotiabank started coverage on shares of AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective on the stock. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Price Performance

ABBV opened at $226.68 on Wednesday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The business has a 50-day moving average of $224.60 and a two-hundred day moving average of $224.45. The stock has a market capitalization of $400.81 billion, a price-to-earnings ratio of 96.05, a price-to-earnings-growth ratio of 0.79 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period last year, the company earned $2.16 earnings per share. The company’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported positive topline results from the Phase 1 multiple ascending dose study of ABBV-295 (long‑acting amylin analog) showing roughly 7.8–9.8% mean weight loss at ~12 weeks and a favorable tolerability profile — supports further development in chronic weight management and expands non‑incretin obesity options. AbbVie reports topline data from Phase I ABBV-295 trial
• Positive Sentiment: AbbVie announced positive Phase 3 AFFIRM results for SKYRIZI (risankizumab) subcutaneous induction in Crohn’s disease — a potential label/indication expansion that could extend revenue runway for an existing franchise. AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study
• Positive Sentiment: Industry coverage highlights ABBV‑295 and early obesity program data (up to ~10% weight loss) as a differentiator vs. incretin therapies — this boosts perception of AbbVie’s cardiometabolic pipeline optionality. AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study
• Positive Sentiment: J.P. Morgan reiterated its Buy stance on ABBV, an institutional vote of confidence that can support demand for the shares. J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
• Neutral Sentiment: Citi’s Geoff Meacham maintained a Hold and $230 price target, signaling caution despite pipeline promise and limiting upside from analyst revisions. Neutral Hold on AbbVie as Early Cardiometabolic Pipeline Shows Promise but Trails Leading Competitors
• Neutral Sentiment: ResearchAndMarkets published an Elahere (mirvetuximab) market report outlining growth drivers in ovarian cancer — useful long‑term market context but not an immediate mover for ABBV shares. Elahere (AbbVie: mirvetuximab soravtansine-gynx) Market Research Report 2026
• Neutral Sentiment: AbbVie’s presentation/transcript at the Leerink Global Healthcare Conference provides management insight on growth drivers and pipeline prioritization — useful for modeling but not an immediate catalyst. AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Negative Sentiment: ICER (cost‑effectiveness body) will review AbbVie’s Parkinson’s drug — an adverse assessment could limit pricing power/reimbursement and pressure long‑term revenue assumptions. ICER to review AbbVie’s Parkinson’s disease drug
• Negative Sentiment: Governance/headline risks: CEO Robert Michael received a sizable pay increase to $32.5M in year two, and an AbbVie SVP sold ~$1.22M in shares — both items can weigh on sentiment among governance‑focused investors. AbbVie’s Robert Michael earns hefty pay bump to $32.5M in 2nd year as CEO AbbVie (NYSE:ABBV) SVP Sells $1,221,518.80 in Stock

Insiders Place Their Bets

In related news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is owned by company insiders.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.